RNA

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Retrieved on: 
Monday, June 24, 2024

Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board.

Key Points: 
  • Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board.
  • “We have assembled a world-class team of scientific and business leaders on our board, and I am delighted to continue these efforts with the addition of Sarah Boyce to Contineum’s Board of Directors,” said Carmine Stengone, President and Chief Executive Officer of Contineum.
  • Ms. Boyce also previously served on the Board of Directors of Berkeley Lights Inc. (Nasdaq: BLI) and currently serves on the board of directors of OmniAb, Inc. Ms. Boyce received a B.S.
  • I am excited about Contineum’s science and development programs and I believe Contineum has a very bright future,” added Sarah Boyce.

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Retrieved on: 
Thursday, June 20, 2024

In the double-blind placebo-controlled treatment period, zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks to patients with a median baseline Lp(a) of approximately 215 nmol/L.

Key Points: 
  • In the double-blind placebo-controlled treatment period, zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks to patients with a median baseline Lp(a) of approximately 215 nmol/L.
  • These data demonstrated a highly significant reduction from baseline in Lp(a) compared to placebo to 48 weeks (end of treatment and dosing period).
  • Median maximum Lp(a) reduction of approximately 90% or greater was observed for both doses during the treatment period.
  • The study is ongoing, and patients will be followed through to week 60 (end of study).

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Retrieved on: 
Thursday, June 20, 2024

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors.
  • Moncef Slaoui brings extraordinary strategic expertise in pharmaceutical product innovation, development and commercialization of several therapeutics and vaccines,” said Joseph Payne, President & Chief Executive Officer of Arcturus.
  • “We warmly welcome Moncef to the Board of Directors and look forward to working with him as we advance our pipeline of next generation mRNA medicines.”
    “I am delighted to join the Board of Arcturus Therapeutics as we embark on this exciting phase of growth,” said Dr. Moncef Slaoui.
  • “I look forward to helping advance the Arcturus pipeline of mRNA vaccines and therapeutics utilizing the next-generation STARR® self-amplifying mRNA and LUNAR® delivery technology platforms.”
    Dr. Moncef Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed.

Translating Breakthroughs from Lab to Market, The Engine Ventures Scales its Pioneering Tough Tech Investment Model

Retrieved on: 
Tuesday, June 18, 2024

Formed in 2016 as The Engine built by MIT, the firm’s mission is to unlock commercialization in Tough Tech, a new asset class that translates breakthrough science and engineering from lab to market.

Key Points: 
  • Formed in 2016 as The Engine built by MIT, the firm’s mission is to unlock commercialization in Tough Tech, a new asset class that translates breakthrough science and engineering from lab to market.
  • The investment fund, now branded as The Engine Ventures, has backed 56 transformational companies.
  • With Fund III, The Engine Ventures is further scaling its investment model to help bridge the gap from discovery to commercialization for climate, human health, and advanced systems technology.
  • With Fund III, we have an incredible opportunity to scale our pioneering investment model and back more game-changing companies with our capital, operational knowledge and academic expertise.”

Ethris Announces $5 Million in Funding to Prepare Lead Candidate ETH47 for Phase 2 Study

Retrieved on: 
Tuesday, June 18, 2024

Ethris GmbH , a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today that it has received funding from the Gates Foundation to support the advancement of the company’s lead mRNA-based product candidate, ETH47.

Key Points: 
  • Ethris GmbH , a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today that it has received funding from the Gates Foundation to support the advancement of the company’s lead mRNA-based product candidate, ETH47.
  • This funding of $5 million includes an equity investment component expected to close at the company’s next financing round.
  • “Ethris’ lead mRNA-based product candidate ETH47 was designed to have broad antiviral capabilities, placing it in a distinct position to address a range of virus-induced respiratory infections and chronic respiratory diseases.
  • A Phase 1 study is ongoing with Ethris’ inhaled mRNA candidate ETH47 to evaluate safety, tolerability, and target engagement in healthy participants.

Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections

Retrieved on: 
Monday, June 17, 2024

“These data offer a compelling look at our real-world experience of using mNGS to uncover the cause of difficult-to-diagnose central nervous system infections to guide timely management and treatment for these life-threatening conditions.”

Key Points: 
  • “These data offer a compelling look at our real-world experience of using mNGS to uncover the cause of difficult-to-diagnose central nervous system infections to guide timely management and treatment for these life-threatening conditions.”
    The study by Benoit, et al.
  • presented at the conference evaluated more than 4,800 patients, who received cerebrospinal fluid (CSF) mNGS testing between 2016 and 2023.
  • “These studies add to the body of evidence that shows metagenomic testing should be part of routine diagnosis for patients with neurological infections.
  • Ultimately, Delve Neuro will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses.

SAPA-GP Hosted the Third @Philly Cell and Gene Therapy Annual Conference

Retrieved on: 
Tuesday, June 18, 2024

On June 14-15, SAPA-GP held the 2024 @Philly Cell and Gene Therapy Annual Conference at the Sheraton Valley Forge Hotel in King of Prussia, northwest of Philadelphia.

Key Points: 
  • On June 14-15, SAPA-GP held the 2024 @Philly Cell and Gene Therapy Annual Conference at the Sheraton Valley Forge Hotel in King of Prussia, northwest of Philadelphia.
  • Inaugurated in 2022, the annual conference has become a leading platform in the region to showcase the latest developments in cell, gene, and RNA therapies, and to connect biotech entrepreneurs with investors.
  • View the full release here: https://www.businesswire.com/news/home/20240617792223/en/
    Dr. Yufeng Li, the conference co-chair and president of SAPA-GP, opened the conference.
  • The 2025 @Philly Cell and Gene Therapy Annual Conference will be held in June 2025.

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular Profiling in the Middle East and Africa

Retrieved on: 
Monday, June 24, 2024

SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling services in the Middle East and Africa (MEA).

Key Points: 
  • SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling services in the Middle East and Africa (MEA).
  • This expansion follows the initial January 2023 distribution rights partnership with Caris for the same services in Southeast Asia (SEA).
  • Juniper is now poised to offer Caris' advanced solid tumour molecular profiling services across a broader region, enhancing patient access to personalised treatment options.
  • "Caris is pleased to expand the distribution of our molecular profiling services in the Middle East and Africa through our partnership with Juniper Biologics," said Caris President David Spetzler, MS, PhD, MBA.

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular Profiling in the Middle East and Africa

Retrieved on: 
Monday, June 24, 2024

SINGAPORE, June 24, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling services in the Middle East and Africa (MEA).

Key Points: 
  • SINGAPORE, June 24, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling services in the Middle East and Africa (MEA).
  • This expansion follows the initial January 2023 distribution rights partnership with Caris for the same services in Southeast Asia (SEA).
  • Juniper is now poised to offer Caris' advanced solid tumour molecular profiling services across a broader region, enhancing patient access to personalised treatment options.
  • "Caris is pleased to expand the distribution of our molecular profiling services in the Middle East and Africa through our partnership with Juniper Biologics," said Caris President David Spetzler, MS, PhD, MBA.

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Molecular Profiling in the Middle East and Africa

Retrieved on: 
Sunday, June 23, 2024

SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling services in the Middle East and Africa (MEA).

Key Points: 
  • SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, has been granted distribution rights for Caris Life Sciences (Caris)' solid tumour molecular profiling services in the Middle East and Africa (MEA).
  • This expansion follows the initial January 2023 distribution rights partnership with Caris for the same services in Southeast Asia (SEA).
  • Juniper is now poised to offer Caris' advanced solid tumour molecular profiling services across a broader region, enhancing patient access to personalised treatment options.
  • "Caris is pleased to expand the distribution of our molecular profiling services in the Middle East and Africa through our partnership with Juniper Biologics," said Caris President David Spetzler, MS, PhD, MBA.